What SSI Diagnostica does

SSI Diagnostica Group (legally SSI Diagnostica A/S, headquartered in Hillerød, Denmark) is a privately held in vitro diagnostics (IVD) company specializing in infectious disease detection across gastrointestinal, respiratory, bloodborne, and general microbiology disease areas. Scientific roots trace to the Statens Serum Institut (founded 1902); the entity was spun out in 1998 and acquired by Adelis Equity Partners in 2016. The Group today operates five to seven integrated brand portfolios (SSI Diagnostica, TECHLAB, Beijing Genesee Biotech, CTK Biotech, Gulf Coast Scientific, InDevR, and FAN GmbH), employing approximately 600 staff across 11 sites in Denmark, the United States, and China, and delivers diagnostic solutions to more than 130 countries.

The product portfolio is split into two streams. Life Science Solutions supplies antisera, antigens, reference bacterial strains, culture media, multiplexed potency assays (VaxArray), and digital interpretation systems (CypherOne) to vaccine manufacturers, CROs, and reference laboratories — including proprietary content libraries covering 92 pneumococcus serotypes, comprehensive Salmonella coverage, and full E. coli O/H/K/F typing. Diagnostic Solutions delivers finished IVD products (lateral flow immunoassays under the QUIK CHEK platform, ELISA, the PyloPLUS urea breath test, FAN breath test devices, and the Flexicult urinalysis kit) to hospital labs, reference labs, and public health programs, with 60+ million tests produced annually.

The Group runs a hybrid go-to-market combining direct enterprise field sales in the Nordics and USA with a network of distribution partners for global reach. Revenue is generated through one-time product sales and contract manufacturing/customization services, with quote-based enterprise pricing and no disclosed subscription model. Strategic customers include GSK (vaccine development, 40+ years), US reference laboratories, and hospital networks. Revenue is approximately 850 mDKK (~$125 mUSD) on a post-Gulf Coast Scientific basis per the April 2025 acquisition announcement.

Name

SSI Diagnostica

Legal name

SSI Diagnostica A/S

Website

https://ssid.com

Company type

Private

Founded year

1902

Operating status

Operating

Headcount range

501–1,000 employees

Short description

SSI Diagnostica Group is a Danish in vitro diagnostics company developing and manufacturing infectious disease tests (gastrointestinal, respiratory, bloodborne) and life science reagents for vaccine manufacturers, clinical labs, and reference laboratories across 130+ countries, operating five brand portfolios under Adelis Equity Partners ownership.

Ownership category

akta.pro rank

Headquarters

HQ city

Hillerød

HQ country

Denmark

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Diagnostic Solutions Products: Finished in vitro diagnostic products including lateral flow tests, enzyme immunoassays, ELISA platforms, culture media, urea breath testing, and digital readers sold to healthcare professionals and laboratories
2. Life Science Solutions Products: Products used by life science and pharma industry including antisera, antigens, serotyping/multiplexing kits, and instrument solutions for vaccine development and quality control
3. Customization and Contract Manufacturing Services: Customization and contract manufacturing services across all development stages for vaccine manufacturers and IVD industry

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

SSI Diagnostica develops, produces, and sells in vitro diagnostic products for clinical microbiology and veterinary diagnostics, organized into two complementary portfolios. Life Science Solutions provides reagents, serotyping kits, multiplexing assays, reference bacterial strains, and culture media used by vaccine manufacturers, IVD developers, and CROs. Diagnostic Solutions comprises finished IVD products—including lateral flow tests (QUIK CHEK family), ELISAs, urea breath tests, urinary antigen tests, and digital readers—used by hospital, reference, and microbiology laboratories for gastrointestinal, respiratory, and bloodborne infectious disease detection. The group also offers customization and contract manufacturing services across development stages for vaccine and IVD customers.

Product overview

SSI Diagnostica Group offers two complementary portfolios: Life Science Solutions and Diagnostic Solutions. Life Science products include antisera, antigens, serotyping/multiplexing kits, reference bacterial strains, culture media, and instrument solutions serving vaccine manufacturers, IVD industry, and CROs. Diagnostic Solutions encompass lateral flow tests (QUIK CHEK family), enzyme immunoassays (ELISA), urea breath testing, digital readers, and rapid diagnostic kits for infectious gastrointestinal, respiratory, and bloodborne diseases. The company operates five acquired brands (SSI Diagnostica, CTK Biotech, Beijing Genesee Biotech, TECHLAB, Gulf Coast Scientific, and InDevR) offering over 200 years of combined scientific expertise across more than 130 countries.

Differentiator

Problem solved

Functional benefit

Products and services

• C. DIFF QUIK CHEK COMPLETE Rapid membrane enzyme immunoassay for the simultaneous detection of Clostridioides difficile GDH antigen and toxins A and B in a single reaction well, delivering results in approximately 30 minutes for hospital and reference laboratories.
• C. difficile QUIK CHEK and ELISA Test Family Family of rapid membrane EIAs and ELISAs (C. DIFF CHEK-60, C. DIFFICILE TOX A/B II, C. DIFFICILE TOX-B TEST) for detection of GDH and toxins A/B from Clostridioides difficile in fecal specimens, used by clinical microbiology laboratories.
• Parasitology QUIK CHEK and ELISA Test Family Rapid membrane EIAs and ELISAs (GIARDIA/CRYPTOSPORIDIUM QUIK CHEK, GIARDIA/CRYPTOSPORIDIUM CHEK, GIARDIA II, CRYPTOSPORIDIUM II, TRI-COMBO PARASITE SCREEN, E. HISTOLYTICA QUIK CHEK, E. HISTOLYTICA II) for detection of Giardia, Cryptosporidium, and Entamoeba histolytica antigens in fecal specimens.
• Shiga Toxin QUIK CHEK and CHEK Rapid membrane enzyme immunoassays for the simultaneous qualitative detection and differentiation of Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2) in a single test, used by clinical laboratories for STEC diagnostics.
• ImmuView Urinary Antigen Tests Urinary antigen tests for the detection of Streptococcus pneumoniae alone and in combination with Legionella pneumophila antigens, supporting rapid diagnosis of respiratory infections in hospital laboratories.
• Pneumococcal Antisera (92 serotypes) High-quality antisera for serotyping of Streptococcus pneumoniae covering 92 serotypes, used by vaccine manufacturers, reference labs, and public health authorities for vaccine development, quality control, and epidemiological surveillance.
• Salmonella Antisera and Serotyping Kits Comprehensive antisera range for serotyping of Salmonella serovars, supporting disease surveillance and epidemiological monitoring by reference laboratories and national health authorities.
• E. coli Antisera and Reference Strains Comprehensive antisera range and reference strains for all known E. coli strains covering O, H, K and F antigens, delivered in extract agar or cryogenic vials, used for surveillance and quality control.
• ImmuLex Group B Streptococcus Antisera Polyclonal antibodies sensitized on latex particles for rapid agglutination testing of Group B Streptococcus (Streptococcus agalactiae), used by clinical microbiology laboratories.
• Culture Media Broad variety of culturing media from solid agar plates to liquids in tubes, produced with high quality and precision at state-of-the-art production facilities for microbiology laboratories.
• Flexicult Urinkit Diagnostic aid for urinary tract infections, supporting diagnosis and treatment decisions in clinical settings.
• Animal Blood Products Blood from horses, cattle, rabbits and sheep delivered in various volumes, stabilized by defibrination or anticoagulants for laboratory use.
• Dermatophyte and C. albicans Real-Time PCR Kit

Quantifiable outcome

• 60 million+ diagnostic tests delivered annually
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core.

• FAN GmbHcoreStrategic or Co-development Partner · 1 May 2026Germany-based manufacturer of breath test devices for H. pylori testing. Acquisition secures critical component in breath testing workflow and strengthens SSI's European footprint. Had prior commercial and R&D partnership with Gulf Coast Scientific.
• InDevRcoreStrategic or Co-development Partner · 1 February 2026Colorado-based provider of advanced multiplexed solutions for vaccine testing and quality control. Acquisition adds expertise in influenza and mRNA vaccine QC testing, complementing SSI's pneumococcal vaccine testing leadership. Now exhibiting together at World Vaccine Congress.
• Gulf Coast ScientificcoreStrategic or Co-development Partner · 1 April 2025Florida-based IVD company specialized in Urea Breath Testing for Helicobacter Pylori. Acquisition strengthened SSI's gastrointestinal disease testing portfolio with complementary products.
• TechLab, Inc.coreStrategic or Co-development Partner · 1 August 2022Virginia-based developer and manufacturer of rapid diagnostic tests for gastrointestinal conditions including C. difficile and H. pylori. Acquisition expanded gastric product portfolio and US market presence.
• CTK BiotechcoreStrategic or Co-development Partner · 1 January 2020California-based company providing bloodborne diagnostic solutions including Malaria, HIV, Syphilis, Dengue, Hepatitis tests. Joined SSI Group in 2020 alongside Beijing Genesee Biotech.
• Beijing Genesee Biotech (BGB)coreStrategic or Co-development Partner · 1 January 2020Manufacturing capabilities in China established 2005. Part of 2020 acquisition alongside CTK Biotech, bringing extensive portfolio of bloodborne diagnostic solutions.
• GSKcoreOthersLeading global vaccine manufacturer trusted partner for 40+ years, using SSI Diagnostica Group's high-quality reagents and quality control solutions for vaccine development.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Hardy Diagnostics: US-based specialty microbiology and culture media manufacturer. Directly comparable to SSIDG's culture media production business and microbiology reagent offerings.
• ELITechGroup: Specialty IVD company serving clinical and industrial microbiology markets with reagent kits and instruments. Comparable specialty diagnostics scale and product breadth in microbiology.
• Sekisui Diagnostics: Specialty IVD and clinical chemistry company with comparable reagent and kit portfolio for clinical laboratories. Closely comparable in scale and channel mix for routine IVD products.
• Meridian Bioscience: Specialty diagnostics company historically focused on GI infectious disease testing (C. difficile, H. pylori, enteric pathogens) — directly comparable to SSIDG's TECHLAB franchise in gastrointestinal diagnostics.
• QuidelOrtho: Specialty IVD company focused on rapid immunoassays and infectious disease diagnostics, including lateral flow platforms. Directly comparable to SSIDG's QUIK CHEK business in clinical diagnostics for GI, respiratory, and bloodborne pathogens.

Broad incumbents

• bioMérieux: Global leader in clinical microbiology and industrial diagnostics, with deep overlap in infectious disease IVD, culture media, and immunoassays. Much larger and broader portfolio, but competes head-to-head with SSIDG in microbiology and GI diagnostics.
• Revvity (formerly PerkinElmer): Life sciences and diagnostics company with significant applied genomics, reagents, and specialty diagnostics offerings. Overlaps with SSIDG's life science reagent business and vaccine development support.
• Bio-Rad Laboratories: Established life science and clinical diagnostics company with significant IVD reagent, quality control, and microbiology portfolios. Overlaps with SSIDG in clinical diagnostics reagents and laboratory QC.
• DiaSorin: Specialty IVD company with strong position in immunodiagnostics and infectious disease serology, having acquired Luminex for multiplexing. Comparable to SSIDG's Life Science Solutions in immunoassay reagents and vaccine QC adjacencies.
• Hologic: Large molecular diagnostics and women's health company with significant infectious disease testing presence. Competes with SSIDG in respiratory and bloodborne pathogen testing through molecular platforms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/statens-serum-institut
• Xx.com/ssi_dk

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SSI Diagnostica